2015 American Transplant Congress
Once-a-Day Administration of CNIs, mTOR and MMF Is Safe in De Novo Renal Transplant Recipients: 1-Year Results of a Pilot Study
Surgery - Renal Transplant Unit, Catholic University of the Sacred Heart, Rome, Italy.
Introduction. The half-lives of Tacrolimus, Everolimus, Cyclosporine and Mofetil Micofenolate (MMF) are respectively: 43, 30, 27 and 18 hours. Once-daily dosing of these drugs is…2015 American Transplant Congress
12-Month Athena Study: Everolimus Vs. Standard Regimen in De Novo Renal Transplant Recipients
1Athena Study Group, Germany; 2Novartis, Pharma, Germany.
Background: Post-kidney transplant (KTx) long-term and full dose/standard calcineurin inhibitor (CNI) use is associated with an increased risk for malignancies, cardiovascular disease, and renal failure.…2015 American Transplant Congress
Clinically Relevant Wound Events With Everolimus-Based Immunosuppressive Regimen: Post-Hoc Analysis from a Randomized Heart Transplant Study
1For the A2309 Study Group, Vienna, Austria; 2Novartis, Basel, Switzerland.
Purpose: In the A2310 (NCT00300274) heart transplant (HTx) study with everolimus (EVR) vs mycophenolate mofetil (MMF), information on a broad spectrum of potential wound healing…2015 American Transplant Congress
10 Year Experience Using a Steroid Free Three Drug Maintenance Immunosuppression Regimen for Pancreas Transplant Alone: Comparison of Induction With Rabbit Antithymocyte Globulin +/- Rituximab
Graft survival following pancreas transplant alone (PTA) is inferior to other pancreas transplants. Steroid elimination is appealing, but a two drug maintenance strategy may be…2015 American Transplant Congress
Effect of Everolimus on Left Ventricular Hypertrophy in De Novo Kidney Transplant Recipients: 12-Month Results from the ELEVATE Study
Background: Left ventricular hypertrophy (LVH) is common in kidney transplant recipients (KTxR) and has shown to be a risk factor for death and heart failure…2015 American Transplant Congress
Plasmapheresis – A Previously Unrecognised Risk Factor for BK Viraemia
BK nephropathy is an important preventable cause of graft loss, with the only universally accepted risk factor being overall burden of immunosuppression. In the absence…2015 American Transplant Congress
De Novo Once-Daily Tacrolimus in Liver Transplantation: Long-Term Outcomes of a Single Center Cohort of 150 Patients
Purpose: To describe the long-term safety and efficacy profile of de novo once-daily tacrolimus (Tac QD) in orthotopic liver transplantation (OLT)Patients and methods: A retrospective…2015 American Transplant Congress
Relative In Vitro Immunoregulatory Effects of Everolimus, Sirolimus, Tacrolimus, Mycophenolic Acid and Drug Combinations
Everolimus (EVL) is a modified form of the mTOR-inhibitor Sirolimus (SRL) and is used clinically in combination with Mycophenolate (MMF) and/or Tacrolimus (TAC). The purpose…2015 American Transplant Congress
Efficacy, Safety and Pharmacokinetics of Once-Daily, MeltDose® Tacrolimus (Envarsus® XR) Versus Twice-Daily Tacrolimus (Prograf®) in De Novo Kidney Transplant Recipient Sub-Groups: A 2 Year Phase 3 Randomized, Double-Blind, Double-Dummy, Trial
Differences in tacrolimus (tac) metabolism are evident in certain populations; in particular, lower tac bioavailability has been shown in females and black kidney transplant recipients…2015 American Transplant Congress
Identification of Genetic Variants Associated With Variation of Tacrolimus Levels in African Americans Using GWAS
African American kidney transplant recipients (AA) have a higher incidence of allograft failure when compared to Caucasians. We have previously reported that tacrolimus troughs (TT)…
American Transplant Congress abstracts